UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 61

Sortiert nach

The electrochemical corrosion behaviour of compacted (Bi, Pb)-2223 superconductors in aqueous solutions

Scientific reports, 2022-10, Vol.12 (1), p.17941-17941, Article 17941

2022

Link zum Volltext

Verfügbarkeit prüfen

Macrophage Profiling in Head and Neck Cancer to Improve Patient Prognosis and Assessment of Cancer Cell–Macrophage Interactions Using Three-Dimensional Coculture Models

International journal of molecular sciences, 2023-08, Vol.24 (16), p.12813

2023

Link zum Volltext

Verfügbarkeit prüfen

RTK Inhibitors in Melanoma: From Bench to Bedside

Cancers, 2021-04, Vol.13 (7), p.1685

2021

Link zum Volltext

Verfügbarkeit prüfen

Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11 , 1093

Cancers, 2023-12, Vol.15 (24), p.5860

2023

Link zum Volltext

Verfügbarkeit prüfen

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma

Cells (Basel, Switzerland), 2022-03, Vol.11 (7), p.1157

2022

Link zum Volltext

Verfügbarkeit prüfen

ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy

Cancer cell international, 2024-01, Vol.24 (1), p.8-8, Article 8

2024

Link zum Volltext

Verfügbarkeit prüfen

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value

Frontiers in oncology, 2021-11, Vol.11, p.780654-780654

2021

Link zum Volltext

Verfügbarkeit prüfen

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma

Cancers, 2019-08, Vol.11 (8), p.1093

2019

Link zum Volltext

Verfügbarkeit prüfen

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma

Cancers, 2020-02, Vol.12 (2), p.512

2020

Link zum Volltext

Verfügbarkeit prüfen

Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies

Cells (Basel, Switzerland), 2023-07, Vol.12 (14), p.1855

2023

Link zum Volltext

Verfügbarkeit prüfen

Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis

Cancers, 2020-05, Vol.12 (5), p.1323

2020

Link zum Volltext

Verfügbarkeit prüfen

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance

Cells (Basel, Switzerland), 2022-11, Vol.11 (22), p.3663

2022

Link zum Volltext

Verfügbarkeit prüfen

Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms

Biology (Basel, Switzerland), 2020-08, Vol.9 (8), p.218

2020

Link zum Volltext

Verfügbarkeit prüfen

The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma

Frontiers in medicine, 2023-05, Vol.10, p.1149918-1149918

2023

Link zum Volltext

Verfügbarkeit prüfen

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

Cancers, 2017-12, Vol.9 (12), p.172

2017

Link zum Volltext

Verfügbarkeit prüfen

Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers 2020, 12, 512

Cancers, 2020-10, Vol.12 (10), p.2981

2020

Link zum Volltext

Verfügbarkeit prüfen

New Drug Combination Strategies in Melanoma: Current Status and Future Directions

Anticancer research, 2017-11, Vol.37 (11), p.5941

2017

Link zum Volltext

Verfügbarkeit prüfen

Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma

Nature cell biology, 2020-08, Vol.22 (8), p.986

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1082: Regorafenib resistance is associated with senescence-like phenotype and EMT in colorectal cancer (CRC)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1082-1082

2021

Link zum Volltext

Verfügbarkeit prüfen

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition

European journal of cancer (1990), 2017-09, Vol.83, p.154-165

2017

Link zum Volltext

Verfügbarkeit prüfen

Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit

Molecular cancer research, 2021-07, Vol.19 (7), p.1221-1233

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of pelletization pressure on the physical and mechanical properties of (Bi, Pb)-2223 superconductors

Physica scripta, 2020-06, Vol.95 (6), p.65702

2020

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to ‘p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib’[Eur J of Cancer 55 (2016) 98–110]

European journal of cancer (1990), 2022-11, Vol.175, p.336-338

2022

Link zum Volltext

Verfügbarkeit prüfen

p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib

European journal of cancer (1990), 2016-03, Vol.55, p.98

2016

Link zum Volltext

Verfügbarkeit prüfen

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

Oncotarget, 2018-08, Vol.9 (61), p.31888-31903

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(58)
Tagungsberichte
(3)

Sprache

Englisch
(61)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The electrochemical corrosion behaviour of compacted (Bi, Pb)-2223 superconductors in aqueous solutions

Macrophage Profiling in Head and Neck Cancer to Improve Patient Prognosis and Assessment of Cancer Cell–Macrophage Interactions Using Three-Dimensional Coculture Models

RTK Inhibitors in Melanoma: From Bench to Bedside

Correction: Krayem et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 2019, 11 , 1093

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma

ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma

Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies

Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance

Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms

The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers 2020, 12, 512

New Drug Combination Strategies in Melanoma: Current Status and Future Directions

Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma

Abstract 1082: Regorafenib resistance is associated with senescence-like phenotype and EMT in colorectal cancer (CRC)

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition

Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit

Effect of pelletization pressure on the physical and mechanical properties of (Bi, Pb)-2223 superconductors

Corrigendum to ‘p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib’[Eur J of Cancer 55 (2016) 98–110]

p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

Suchergebnisse filtern